Going forward, Natera said it will market its Panorama NIPT assay and carrier screening test Horizon directly to physicians.
Around 16,000 4Kscore prostate cancer tests were performed in Q3, which is a 365 percent increase over Q3 2015.
Experts said that the EMR is a crucial channel for aggregating clinical insights from multiple sources, but plenty of work is needed to achieve broader adoption.
The company, which is part of Opko Health's BioReference Laboratories, recently hired a new managing director, who plans to expand the firm's market and testing portfolio.
The two entities also plan to work together using the data generated from the tests to do added research.
The performance of WES for genetically heterogeneous disorders improves significantly when testing is performed on the proband and two or more family members.
The partners will develop an NGS panel for solid and liquid tumors for use in personalized oncology.
The company joins the Pistoia Alliance as a participating member and the Global Alliance for Genomics and Health as an organizational member.
In a statement to GenomeWeb, Myriad noted that all seven of its cases are now settled, "which ends the BRCA litigation."
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.